Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment

Haematologica. 2023 Sep 21. doi: 10.3324/haematol.2023.283940. Online ahead of print.ABSTRACTWe evaluated patients with relapsed multiple myeloma with renal impairment (RI treated with standard of care ide-cel, as outcomes with CAR-T therapy are unknown in this population. RI was defined as creatinine clearance (CrCl < 50 ml/min. CrCl of < 30 ml/min or dialysis dependence were defined as severe RI. The study cohort included 214 patients, 28 (13% patients with RI, including 11 patients severe RI (dialysis, n=1. Patients with RI were older, more likely to be female and had higher likelihood of having R-ISS stage 3 disease. Rates and severity of CRS (89% vs 84%, grade ≥ 3: 7% vs 2% and ICANS (23% vs 20% were similar in patients with and without RI, respectively. Patients with RI had higher incidence of short-term ≥ grade 3 cytopenias, although cytopenias were similar by 3 months following CAR-T. Renal function did not worsen after CAR-T in patients with RI. Response rates (93% vs 82% and survival outcomes (median PFS: 9 vs 8 months, p=0.26 were comparable in patients with and without RI, respectively. Treatment with ide-cel is feasible in patients with RI, with a comparable safety and efficacy profile as patients without RI, with notable exception of higher short-term high-grade cytopenias.PMID:37731379 | DOI:10.3324/haematol.2023.283940

Source: Haematologica - September 21, 2023 Category: Hematology Authors: Surbhi Sidana Lauren C Peres Hamza Hashmi Hitomi Hosoya Christopher Ferreri Jack Khouri Danai Dima Shebli Atrash Peter Voorhees Gary Simmons Douglas W Sborov Nilesh Kalariya Vanna Hovanky Sushma Bharadwaj David Miklos Charlotte Wagner Mehmet H Kocoglu Gur Source Type: research